Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling

Cellular Signalling

Volumn 26, Issue 2, 2014, Pages 352-362

  Garulli, Chiara ^a   Kalogris, Cristina ^a   Pietrella, Lucia ^a   Bartolacci, Caterina ^a   Andreani, Cristina ^a   Falconi, Maurizio ^a   Marchini, Cristina ^a   Amici, Augusto ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Bone morphogenic proteins; Breast cancer; Dorsomorphin; EMT (epithelial mesenchymal transition); Mesenchymal cancer stem cells

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CYCLOOXYGENASE 2; CYTOKERATIN 18; DORSOMORPHIN; PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN;

ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CANCER STEM CELL; CARCINOGENICITY; CELL INVASION; CELL MOTILITY; CELL RENEWAL; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PLASTICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

GASTROPODA;

BONE MORPHOGENIC PROTEINS; BREAST CANCER; DORSOMORPHIN; EMT (EPITHELIAL-MESENCHYMAL TRANSITION); MESENCHYMAL CANCER STEM CELLS;

ANIMALS; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; BONE MORPHOGENETIC PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CYCLOOXYGENASE 2; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; MICE; NEOPLASTIC STEM CELLS; PHENOTYPE; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84890033223     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2013.11.022     Document Type: Article

References (36)

1. Miyazono K., et al. J. Biochem. 2010, 147:35-51.
2. Miyazono K., et al. Cytokine Growth Factor Rev. 2005, 16:251-263.
3. Derynck R., et al. Nature 2003, 425:577-584.
4. Heldin C.H., et al. Nature 1997, 390:465-471.
5. Thawani J.P., et al. Neurosurgery 2010, 66:233-246.
6. Ketolainen J.M., et al. Breast Cancer Res. Treat. 2010, 124:377-386.
7. Varga A.C., et al. Oncogene 2005, 24:5713-5721.
8. Dutko J.A., et al. Cell 2011, 145:636.
9. Galiè M., et al. Oncogene 2008, 27:2542-2551.
10. Marchini C., et al. PLoS One 2010, 5:e14131.
11. Singh-Ranger G., et al. Breast Cancer Res. Treat. 2008, 109:189-198.
12. Galiè M., et al. Carcinogenesis 2005, 26:1868-1878.
13. Galie M., et al. Neoplasia 2005, 7:528-536.
14. Zalvide J., et al. Mol. Cell. Biol. 1995, 15:5800-5810.
15. Dontu G., et al. Genes Dev. 2003, 17:1253-1270.
16. Debnath J., et al. Methods 2003, 30:256-268.
17. Bisaro B., et al. Breast Cancer Res. 2012, 14:137-148.
18. Yokota Y., et al. J. Cell. Physiol. 2002, 190:21-28.
19. Korchynskyi O., ten Dijke P. J. Biol. Chem. 2002, 277:4883-4891.
20. Hong C.C., et al. Cytokine Growth Factor Rev. 2009, 20:409-418.
21. Yu P.B., et al. Nat. Chem. Biol. 2008, 4:33-41.
22. Kalluri R., et al. J. Clin. Invest. 2009, 119:1420-1428.
23. Polyak K., et al. Nat. Rev. Cancer 2009, 9:265-273.
24. Ponti D., et al. Cancer Res. 2005, 65:5506-5511.
25. Susperregui A.R., et al. Mol. Endocrinol. 2011, 25:1006-1017.
26. Reya T., et al. Nature 2001, 414:105-111.
27. Thériault B.L., et al. Carcinogenesis 2007, 28:1153-1162.
28. Balboni A.L., et al. Cancer Res. 2013, 73:1020-1030.
29. Guo D., et al. Mol. Cell. Biochem. 2012, 363:179-190.
30. Chiu C.Y., et al. Mol. Cancer Res. 2012, 10:415-427.
31. Clement J.H., et al. Int. J. Oncol. 2005, 27:401-407.
32. Maegdefrau U., et al. Exp. Mol. Pathol. 2012, 92:74-81.
33. Katsuno Y., et al. Oncogene 2008, 27:6322-6333.
34. Mani S.A., et al. Cell 2008, 133:704-715.
35. Bailey J.M., et al. J. Cell. Biochem. 2007, 102:829-839.
36. Dave B., et al. Breast Cancer Res. 2012, 14:202-206.